European guidelines for clinical management of abnormal cervical cytology, Part 2
European guidelines for clinical management of abnormal cervical cytology, Part 2
复制标题
DOI：
10.1111/j.1365-2303.2008.00636.x
复制
发表时间：
2009-02-01
期刊：
影响因子：
1.3
通讯作者：
Prendiville, W.
中科院分区：
文献类型：
--
作者：
Jordan, J.;Martin-Hirsch, P.;Prendiville, W.
本文介绍了《欧洲宫颈癌筛查质量保证指南》第二版第6章的第二部分。同一章的第一部分发表在上一期（细胞学2008；19:32 42-54）。本部分提供了如何管理和治疗组织学证实的宫颈上皮内瘤变妇女的指导。本文介绍了切除和消融治疗方法的特点、适应证和可能的并发症。讨论了治疗后监测结果的三种选择（重复细胞学检查、HPV检测和阴道镜检查）。针对特殊的临床情况提供了具体的建议：怀孕、免疫抑制、HIV感染、绝经后、青春期和细胞-阴道-组织学差异。论文最后对患者管理的质量保证提出了建议，并就如何向有关妇女传达筛查、诊断和治疗结果提出了一些一般性建议。最后，附上数据收集表。
The current paper presents the second part of chapter 6 of the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. The first part of the same chapter was published in a previous issue (Cytopathology 2008;19:342-54). This part provides guidance on how to manage and treat women with histologically confirmed cervical intraepithelial neoplasia. The paper describes the characteristics, indications and possible complications of excisional and ablative treatment methods. The three options to monitor the outcome after treatment (repeat cytology, HPV testing and colposcopy) are discussed. Specific recommendations for particular clinical situations are provided: pregnancy, immuno-suppression, HIV infection, post-menopause, adolescence and cyto-colpo-histological disparity. The paper ends with recommendations for quality assurance in patient management and some general advice on how to communicate screening, diagnosis and treatment results to the woman concerned. Finally, a data collection form is attached.